Comparative Effectiveness Analysis of Monotherapy With Cytotoxic Agents in Triple-negative Metastatic Breast Cancer in a Community Setting-Reference-Cited by-同舟云学术

Comparative Effectiveness Analysis of Monotherapy With Cytotoxic Agents in Triple-negative Metastatic Breast Cancer in a Community Setting

Published:2015-01 Issue:1 Volume:37 Page:134-144
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Dranitsaris George,Gluck Stefan,Faria Claudio,Cox David,Rugo Hope

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference21 articles.

1. Surveillance Epidemiology and End Results (SEER). National Cancer Institute 2011. Washington, USA, 2013 (http://seer.cancer.gov/). Accessed January 31, 2014.

2. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001

3. Superior efficacy of letrozole versus tamoxifen as first line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group;Mouridsen;J Clin Oncol,2001

4. Trastuzumab emtansine for HER2-positive advanced breast cancer;Verma;N Engl J Med,2012

5. Molecularly targeted therapies for metastatic triple-negative breast cancer;Bayraktar;Breast Cancer Res Treat,2013

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial;npj Breast Cancer;2022-09-20

2. Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer;Cancers;2020-03-19

3. The safety of eribulin for the treatment of metastatic breast cancer;Expert Opinion on Drug Safety;2019-05-04

4. Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer;Future Oncology;2019-05

5. Utility of the Absolute Lymphocyte Count and Neutrophil/Lymphocyte Ratio for Predicting Survival in Patients with Metastatic Breast Cancer on Eribulin: A Real-World Observational Study;Chemotherapy;2019